The Comprehensive Sickle Cell Center is now in its night year of operation. In the past nine years the investigators and their colleagues have been witness to real progress in the management of sickle cell diseases (SCD). For the first time there are therapeutic options available to some patients: The overall outcome for children with sickle cell disease born and resident in the United States has never been better. However, the fundamental problems of sickle cell disease have not been solved. Many patients in the United States and elsewhere still can only expect lives full of pain and illness and ultimately death at a relatively early age. The overall goal of this Center is to seek new information while applying acquired knowledge to the full benefit of the patient. To accomplish this goal the investigators propose interrelated laboratory research projects that may lead to more efficient methods of gene therapy or the development of effective anti- sickling agents. The investigators will test therapeutic agents on a more realistic transgenic mouse model for sickle cell disease and be able to evaluate the results with sophisticated image analyses systems. In the clinical projects, the investigators seek to improve the nutritional and growth status of children with sickle cell disease in clinical trials using zinc and calcium and in a behavioral modification program to increase caloric intake. The investigators propose a long-term toxicity study of hydroxyurea therapy in children as continuation of the current Phase II study. In the era of cost-conscious health care, the investigators evaluate the economic impact of a practice change in the management of the febrile child with sickle cell disease. The investigators consolidate the education programs into one three-part project that addresses professional education in sickle cell disease as well as evaluate a formal program of transition of older adolescents to adult services. In the testing and counseling area, the investigators have adopted the high technology microchip technology to the diagnosis of sickle cell disease at the single cell level. And, the investigators develop a model of culturally sensitive genetic counseling program in a newborn screening project in a developing country.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Comprehensive Center (P60)
Project #
5P60HL038632-14
Application #
6389031
Study Section
Special Emphasis Panel (ZHL1-CSR-Q (S1))
Program Officer
Evans, Gregory
Project Start
1988-04-10
Project End
2003-03-31
Budget Start
2001-04-01
Budget End
2002-03-31
Support Year
14
Fiscal Year
2001
Total Cost
$2,056,484
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ballas, Samir K; Connes, Philippe; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (2018) Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and ?-thalassemia. Eur J Haematol 101:798-803
Kwiatkowski, Janet L; Zimmerman, Robert A; Pollock, Avrum N et al. (2009) Silent infarcts in young children with sickle cell disease. Br J Haematol 146:300-5
Adachi, Kazuhiko; Ding, Min; Asakura, Toshio et al. (2009) Relationship between beta4 hydrogen bond and beta6 hydrophobic interactions during aggregate, fiber or crystal formation in oversaturated solutions of hemoglobin A and S. Arch Biochem Biophys 481:137-44
Kiryu, Shigeru; Sundaram, Tessa; Kubo, Shigeto et al. (2008) MRI assessment of lung parenchymal motion in normal mice and transgenic mice with sickle cell disease. J Magn Reson Imaging 27:49-56
Niebanck, Alison E; Pollock, Avrum N; Smith-Whitley, Kim et al. (2007) Headache in children with sickle cell disease: prevalence and associated factors. J Pediatr 151:67-72, 72.e1
Uematsu, Hidemasa; Takahashi, Masaya; Hatabu, Hiroto et al. (2007) Changes in T1 and T2 observed in brain magnetic resonance imaging with delivery of high concentrations of oxygen. J Comput Assist Tomogr 31:662-5
Obata, Kazuo; Mattiello, Julian; Asakura, Kenji et al. (2006) Exposure of blood from patients with sickle cell disease to air changes the morphological, oxygen-binding, and sickling properties of sickled erythrocytes. Am J Hematol 81:26-35
Akbar, Mohammed G K; Tamura, Yutaka; Ding, Min et al. (2006) Inhibition of hemoglobin S polymerization in vitro by a novel 15-mer EF-helix beta73 histidine-containing peptide. Biochemistry 45:8358-67
Adachi, Kazuhiko; Ding, Min; Surrey, Saul et al. (2006) The Hb A variant (beta73 Asp-->Leu) disrupts Hb S polymerization by a novel mechanism. J Mol Biol 362:528-38
Asakura, Toshio; Asakura, Kenji; Obata, Kazuo et al. (2005) Blood samples collected under venous oxygen pressure from patients with sickle cell disease contain a significant number of a new type of reversibly sickled cells: constancy of the percentage of sickled cells in individual patients during steady state. Am J Hematol 80:249-56

Showing the most recent 10 out of 140 publications